Veeva Systems Acquires Copli, Launches Falcon MLR to Revolutionize Life Sciences Content Review

Veeva Systems (VEEV) makes significant strides in the life sciences sector through the acquisition of Copli, a notable name in medical, legal, and regulatory (MLR) solutions. This acquisition leads to the introduction of Veeva Falcon MLR, an innovative platform aimed at transforming content review processes in the industry. By leveraging agent-based technology, Veeva Falcon MLR proposes to automate up to 70% of the manual efforts traditionally involved in MLR practices within five years, offering substantial improvements in efficiency and compliance management. The integration of Copli’s technology not only streamlines the review of promotional and medical materials but also empowers reviewers to focus on strategic tasks rather than routine checks, ultimately accelerating the approval process for marketing teams and agencies.

Transformative Potential of Falcon MLR

The leadership at Veeva Systems underscores the transformative potential of Falcon MLR. Jacob Scheel-Bech, CEO of Copli, views this development as a pivotal moment for medical and promotional content review, with implications for reducing bottlenecks in information dissemination to patients and healthcare providers. Emma Hyland, vice president of Veeva Commercial Content, reinforces the importance of this innovation in enabling brands to expedite their review cycles significantly and transition their reviewers toward more strategic advisory roles. Such improvements highlight Veeva's commitment to not just innovation but also to alleviating long-standing challenges within the life sciences compliance landscape.

Webinar and Commitment to Clients

Looking ahead, Veeva has planned a webinar on July 9, 2026, to provide potential users with further insights into Veeva Falcon MLR's capabilities and applications. This initiative exemplifies Veeva's ongoing dedication to supporting over 1,500 customers, ranging from major pharmaceuticals to emerging biotechs. The company positions itself as a leader striving for excellence in the life sciences industry, all while maintaining a balanced approach to stakeholder interests as a Public Benefit Corporation. As Veeva continues to roll out advanced solutions like Falcon MLR, it cements its role as a pivotal force in enhancing operational efficiencies across the sector.